InvestorsHub Logo
Followers 69
Posts 6501
Boards Moderated 0
Alias Born 02/10/2010

Re: chonrm post# 154733

Monday, 10/15/2018 11:26:59 AM

Monday, October 15, 2018 11:26:59 AM

Post# of 330276
"That was a joke",I strongly disagree with that opinion

Did you even read the article?

I have been following BIEL for over 10 years and have never heard that
PSWT could be customized to enhance the effects of a specific drug or for greater effect on specific tissue.

Rather than BIEL only being of interest to those Pharma Companies that want to expand into the Pain Relief Device Market, BIEL is now of interest to any Pharma Company that wants to improve the efficacy of their drugs.

That Pipeline Just Got a Lot Bigger

Targeted Therapy

"That PSWT provides a local, controlled therapy that can be customised to influence specific pain pathways or, alternatively, to adjust to specific tissue characteristics, suggests that that this technology may play a critical role in the future of pain management"



Pharmacological Synergies

"This biological basis suggests that this newly developing field of neuromodulation may be of particular interest to the biopharma industry as the opportunity exists to create specific pulsed EMF pattern to regulate specific biochemical pathways. Alternatively, there is the potential to create products that can be adjusted to the specific tissues being treated, resulting in a type of personalised therapeutic application. Additionally, opportunities exist to develop biopharmacologic products that work synergistically with EMF therapies."

http://www.bielcorp.com/biel/wp-content/uploads/2018/09/Koneru_McLeod_EBR-article.pdf